FS118 First in Human Study in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in adult participants diagnosed with advanced tumors to
characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This is
a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed to
systematically assess safety and tolerability, to identify the maximum tolerated dose (MTD)
and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced tumors and to
determine the efficacy of FS118 in participants with squamous cell carcinoma of the head and
neck (SCCHN). Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be
assessed.